Recruiting
Phase 2

Ivermectin & SOCP

Sponsor:

Memorial Sloan Kettering Cancer Center

Code:

NCT07895498

Conditions

Pancreatic Cancer

Skin Toxicities

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Minocycline

Hypochlorous Acid

Hydrocortison cream

Triamcinolone (TAC) 0.1% cream

Clobetasol

Study Details

Brief summary:

The researchers are doing this study to find out whether the combination of ivermectin and standard of care prophylaxis (SOCP; drugs given to prevent the development of a disease or condition) is an effective treatment approach for people with skin side effects caused by daraxonrasib treatment (daraxonrasib-induced skin toxicity). The researchers will compare the combination of ivermectin and SOCP with SOCP alone to see which treatment approach is more effective. The researchers will also look at how the study treatments impact participants' quality of life. The researchers will measure quality of life by having participants complete questionnaires.

Conditions

Pancreatic Cancer

Skin Toxicities

Study ID

NCT07895498

Start date

Oct 16, 2026

Status verified date

Oct, 2026

Completion date

Oct 16, 2028

Anticipated

Primary completion date

Oct 16, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patients must have advanced pancreatic ductal adenocarcinoma with intent to daraxonrasib as standard of care monotherapy
  • Female or male aged 18 years and older at the time of enrollment.
  • Not pregnant and not nursing.
  • No active infection requiring parenteral antibiotic(s).
  • Patients have no intent to receive other anti-cancer therapy beyond daraxonrasib
  • No history of allergic reaction to the study agent(s), compounds of similar chemical or biologic composition to the study agent(s) (or any of its excipients).
  • Patients who are able to understand and willing to sign the written informed consent form or patients who have impaired decision-making capacity but have a legally authorized representative who can consent on their behalf are eligible. A signed informed consent form must be appropriately obtained prior to the conduct of any trial-specific procedure.

Exclusion Criteria:

  • Concurrent use of another investigational drug or device for the daraxonrasib-induced skin toxicity (i.e., outside of study treatment) during, or within 4 weeks of study treatment.
  • Patients receiving prednisone 10 mg/day or higher (or equivalent) at the time of randomization for indications other than daraxonrasib skin toxicity management.
  • Patients receiving tetracyclines, ivermectin or other systemic medication that could mask daraxonrasib rash development.
  • Pregnancy or planned pregnancy during the study period.
  • Documented allergy to oral ivermectin and / or minocycline
  • Any condition which, in the investigator's opinion, makes the patient unsuitable for trial participation.

Study Design

Enrollment

122 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: SOCP alone

Minocycline Face: Hypochlorous acid solution Face: Hydrocortisone Trunk: Triamcinolone Scalp: Clobetasol propionate Photoprotection: Broad-spectrum sunscreen

experimental: Ivermectin 200 mcg/kg orally weekly plus SOCP

Ivermectin 200mcg/kg orally weekly PLUS SOCP above as in Arm A

Interventions

Minocycline

Minocycline 100mg PO twice daily (or doxycycline alternative)

Hypochlorous Acid

Face: Hypochlorous acid solution applied every morning

Hydrocortison cream

Face: Hydrocortisone 2.5% cream (or equivalent) applied twice daily

Triamcinolone (TAC) 0.1% cream

Trunk: Triamcinolone 0.1% cream (or equivalent) applied twice daily

Clobetasol

Scalp: Clobetasol propionate 0.05% solution (or equivalent) applied twice daily

Photoprotection

Broad-spectrum sunscreen (SPF 30 or higher) applied daily to sun- exposed areas

Ivermectin

Ivermectin 200mcg/kg orally weekly PLUS

Primary outcome measure

  • pustular drug eruption assessed [ Time Frame: Day 56 ± 3 days ]

Central Contacts and Locations

Central contacts

Allison Gordon, MD

646-608-2339gordona3@mskcc.org

Eileen O'Reilly, MD

646-888-4182

Locations

Memorial Sloan Kettering Basking Ridge (All Protocol Activities)

Recruiting

Basking Ridge, New Jersey, United States, 07920

Contacts

Allison Gordon, MD

646-608-2339

Memorial Sloan Kettering Monmouth (Consent Only)

Recruiting

Middletown, New Jersey, United States, 07748

Contacts

Allison Gordon, MD

646-608-2339

Memorial Sloan Kettering Bergen (Consent Only)

Recruiting

Montvale, New Jersey, United States, 07645

Contacts

Allison Gordon, MD

646-608-2339

Memorial Sloan Kettering Suffolk-Commack (Consent Only)

Recruiting

Commack, New York, United States, 11725

Contacts

Allison Gordon, MD

646-608-2339

Memorial Sloan Kettering Westchester (All Protocol Activities)

Recruiting

Harrison, New York, United States, 10604

Contacts

Allison Gordon, MD

646-608-2339

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

Recruiting

New York, New York, United States, 10065

Contacts

Allison Gordon, MD

646-608-2339

Memorial Sloan Kettering Nassau (Consent Only)

Recruiting

Uniondale, New York, United States, 11553

Contacts

Allison Gordon, MD

646-608-2339

More Information

Sponsor

Memorial Sloan Kettering Cancer Center

Last update posted

Oct 26, 2026

Last verified

Oct, 2026

Keywords

  • Ivermectin
  • Daraxonrasib
  • 26-384

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-27. This information was provided to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center on 2026-10-26. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.